ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Partnerships Pursue Drug Conjugation

by Lisa M. Jarvis
December 24, 2012 | APPEARED IN VOLUME 90, ISSUE 52

Celgene will make an undisclosed payment and take a stake in Sutro Biopharma as part of a collaboration to develop antibody-drug conjugates and bispecific antibodies against two undisclosed disease targets. Sutro, which says it could collect up to $500 million if the programs reach the market, will also manufacture a Celgene antibody. In a separate deal, Shire will work with Arrowhead Research to develop peptide-drug conjugates. In addition to research funding, Arrowhead could earn up to $33 million for each drug candidate developed.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment